Cargando…
Cell-bound complement activation products in SLE
Diagnosis of SLE is based on clinical manifestations and laboratory findings. Timely diagnosis and treatment are important to control disease activity and prevent organ damage. However, diagnosis is challenging because of the heterogeneity in clinical signs and symptoms, and also because the disease...
Autores principales: | Ramsey-Goldman, Rosalind, Li, Jian, Dervieux, Thierry, Alexander, Roberta Vezza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704741/ https://www.ncbi.nlm.nih.gov/pubmed/29214038 http://dx.doi.org/10.1136/lupus-2017-000236 |
Ejemplares similares
-
Cell-bound complement activation products associate with lupus severity in SLE
por: Arriens, Cristina, et al.
Publicado: (2020) -
Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE
por: Merrill, Joan T, et al.
Publicado: (2018) -
Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE)
por: Conklin, John, et al.
Publicado: (2022) -
Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus
por: Buyon, Jill, et al.
Publicado: (2016) -
The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus
por: Mossell, James, et al.
Publicado: (2016)